---
document_datetime: 2025-12-29 12:39:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/arsenic-trioxide-medac.html
document_name: arsenic-trioxide-medac.html
version: success
processing_time: 0.1236738
conversion_datetime: 2025-12-30 10:51:33.700143
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Arsenic trioxide medac

[RSS](/en/individual-human-medicine.xml/67354)

##### Authorised

This medicine is authorised for use in the European Union

arsenic trioxide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Arsenic trioxide medac](#news-on)
- [Related content](#related-content-1600)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Arsenic trioxide medac is used to treat adults (aged 18 years or over) with acute promyelocytic leukaemia (APL).

APL is a rare form of leukaemia (cancer of the white blood cells) caused by a genetic 'translocation' (when there is a swap of genes between two chromosomes). The translocation affects the way the white blood cells grow, and as a result they lack the ability to use retinoic acid (vitamin A). Patients with APL are normally treated with retinoids (substances derived from vitamin A).

Arsenic trioxide medac is used in:

- patients with newly diagnosed low or intermediate risk APL where it is used together with the medicine all-trans-retinoic acid (ATRA);
- patients with APL whose disease has not responded to previous treatment with a retinoid and cancer medicines, or when their disease has come back after this type of treatment.

Arsenic trioxide medac is a 'generic medicine'. This means that  Arsenic trioxide medac contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Trisenox.

Arsenic trioxide medac contains the active substance arsenic trioxide.

Expand section

Collapse section

## How is Arsenic trioxide medac used?

Arsenic trioxide medac can only be obtained with a prescription and treatment should be supervised by a doctor who has experience in the management of patients with acute leukaemias. The medicine is given by infusion (drip) into a vein. The infusion should last one to two hours, but the doctor may have to slow it down if the patient has certain side effects.

The recommended dose of Arsenic trioxide medac depends on the patient's body weight. The treatment is divided into 2 phases: induction and consolidation.

During the induction phase, Arsenic trioxide medac is given every day until there are signs that the treatment is working (when the bone marrow no longer contains any leukaemia cells). If this does not happen by day 50 (for previously treated patients) or by day 60 (for newly diagnosed patients), the treatment should be stopped.

During the consolidation phase, Arsenic trioxide medac is given once a day for five days, followed by a two day break, repeated for four or five weeks. The number of times these cycles are repeated depends on whether patients have received previous treatment or not.

For more information about using Arsenic trioxide medac, see the package leaflet or contact your doctor or pharmacist.

## How does Arsenic trioxide medac work?

The active substance in Arsenic trioxide medac, arsenic trioxide, is a chemical that has been used in medicines for many years, including for the treatment of leukaemia. The way it works in this disease is not completely understood. It is thought to prevent the production of DNA (genetic material), which is necessary for leukaemia cells to grow.

## How has Arsenic trioxide medac been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Trisenox, and do not need to be repeated for Arsenic trioxide medac.

As for every medicine, the company provided studies on the quality of Arsenic trioxide medac. There was no need for 'bioequivalence' studies to investigate whether Arsenic trioxide medac is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Arsenic trioxide medac is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.

## What are the benefits and risks of Arsenic trioxide medac?

Because Arsenic trioxide medac is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Arsenic trioxide medac authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Arsenic trioxide medac has been shown to be comparable to Trisenox. Therefore, the Agency's view was that, as for Trisenox, the benefits of Arsenic trioxide medac outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Arsenic trioxide medac?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Arsenic trioxide medac have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Arsenic trioxide medac are continuously monitored. Side effects reported with Arsenic trioxide medac are carefully evaluated and any necessary action taken to protect patients.

## Other information about Arsenic trioxide medac

Arsenic trioxide medac received a marketing authorisation valid throughout the EU on 17 September 2020.

Arsenic trioxide medac : EPAR - Medicine overview

Reference Number: EMA/407447/2020

English (EN) (174.82 KB - PDF)

**First published:** 01/10/2020

[View](/en/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-896)

български (BG) (196.79 KB - PDF)

**First published:**

01/10/2020

[View](/bg/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_bg.pdf)

español (ES) (174.09 KB - PDF)

**First published:**

01/10/2020

[View](/es/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_es.pdf)

čeština (CS) (195.42 KB - PDF)

**First published:**

01/10/2020

[View](/cs/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_cs.pdf)

dansk (DA) (171.9 KB - PDF)

**First published:**

01/10/2020

[View](/da/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_da.pdf)

Deutsch (DE) (177.45 KB - PDF)

**First published:**

01/10/2020

[View](/de/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_de.pdf)

eesti keel (ET) (162.13 KB - PDF)

**First published:**

01/10/2020

[View](/et/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_et.pdf)

ελληνικά (EL) (198.86 KB - PDF)

**First published:**

01/10/2020

[View](/el/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_el.pdf)

français (FR) (175.46 KB - PDF)

**First published:**

01/10/2020

[View](/fr/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_fr.pdf)

hrvatski (HR) (194.2 KB - PDF)

**First published:**

01/10/2020

[View](/hr/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_hr.pdf)

italiano (IT) (172.48 KB - PDF)

**First published:**

01/10/2020

[View](/it/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (212.22 KB - PDF)

**First published:**

01/10/2020

[View](/lv/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (195.78 KB - PDF)

**First published:**

01/10/2020

[View](/lt/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_lt.pdf)

magyar (HU) (196.8 KB - PDF)

**First published:**

01/10/2020

[View](/hu/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_hu.pdf)

Malti (MT) (197.59 KB - PDF)

**First published:**

01/10/2020

[View](/mt/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_mt.pdf)

Nederlands (NL) (173.23 KB - PDF)

**First published:**

01/10/2020

[View](/nl/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_nl.pdf)

polski (PL) (198.34 KB - PDF)

**First published:**

01/10/2020

[View](/pl/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_pl.pdf)

português (PT) (174.75 KB - PDF)

**First published:**

01/10/2020

[View](/pt/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_pt.pdf)

română (RO) (193.76 KB - PDF)

**First published:**

01/10/2020

[View](/ro/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_ro.pdf)

slovenčina (SK) (195.39 KB - PDF)

**First published:**

01/10/2020

[View](/sk/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_sk.pdf)

slovenščina (SL) (193.11 KB - PDF)

**First published:**

01/10/2020

[View](/sl/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_sl.pdf)

Suomi (FI) (171.98 KB - PDF)

**First published:**

01/10/2020

[View](/fi/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_fi.pdf)

svenska (SV) (172.38 KB - PDF)

**First published:**

01/10/2020

[View](/sv/documents/overview/arsenic-trioxide-medac-epar-medicine-overview_sv.pdf)

Arsenic trioxide medac : EPAR - Risk-management-plan summary

English (EN) (151.78 KB - PDF)

**First published:** 01/10/2020

[View](/en/documents/rmp-summary/arsenic-trioxide-medac-epar-risk-management-plan-summary_en.pdf)

## Product information

Arsenic trioxide medac : EPAR - Product information

English (EN) (260.69 KB - PDF)

**First published:** 01/10/2020

**Last updated:** 26/04/2022

[View](/en/documents/product-information/arsenic-trioxide-medac-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-628)

български (BG) (370.96 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/bg/documents/product-information/arsenic-trioxide-medac-epar-product-information_bg.pdf)

español (ES) (326.58 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/es/documents/product-information/arsenic-trioxide-medac-epar-product-information_es.pdf)

čeština (CS) (362.39 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/cs/documents/product-information/arsenic-trioxide-medac-epar-product-information_cs.pdf)

dansk (DA) (320.33 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/da/documents/product-information/arsenic-trioxide-medac-epar-product-information_da.pdf)

Deutsch (DE) (320.85 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/de/documents/product-information/arsenic-trioxide-medac-epar-product-information_de.pdf)

eesti keel (ET) (312.62 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/et/documents/product-information/arsenic-trioxide-medac-epar-product-information_et.pdf)

ελληνικά (EL) (623.96 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/el/documents/product-information/arsenic-trioxide-medac-epar-product-information_el.pdf)

français (FR) (326.44 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/fr/documents/product-information/arsenic-trioxide-medac-epar-product-information_fr.pdf)

hrvatski (HR) (403.31 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/hr/documents/product-information/arsenic-trioxide-medac-epar-product-information_hr.pdf)

íslenska (IS) (246.37 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/is/documents/product-information/arsenic-trioxide-medac-epar-product-information_is.pdf)

italiano (IT) (283.62 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/it/documents/product-information/arsenic-trioxide-medac-epar-product-information_it.pdf)

latviešu valoda (LV) (351.61 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/lv/documents/product-information/arsenic-trioxide-medac-epar-product-information_lv.pdf)

lietuvių kalba (LT) (340.88 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/lt/documents/product-information/arsenic-trioxide-medac-epar-product-information_lt.pdf)

magyar (HU) (310.83 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/hu/documents/product-information/arsenic-trioxide-medac-epar-product-information_hu.pdf)

Malti (MT) (363.55 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/mt/documents/product-information/arsenic-trioxide-medac-epar-product-information_mt.pdf)

Nederlands (NL) (281.27 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/nl/documents/product-information/arsenic-trioxide-medac-epar-product-information_nl.pdf)

norsk (NO) (254.1 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/no/documents/product-information/arsenic-trioxide-medac-epar-product-information_no.pdf)

polski (PL) (353.37 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/pl/documents/product-information/arsenic-trioxide-medac-epar-product-information_pl.pdf)

português (PT) (247.72 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/pt/documents/product-information/arsenic-trioxide-medac-epar-product-information_pt.pdf)

română (RO) (348.93 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/ro/documents/product-information/arsenic-trioxide-medac-epar-product-information_ro.pdf)

slovenčina (SK) (338.03 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/sk/documents/product-information/arsenic-trioxide-medac-epar-product-information_sk.pdf)

slovenščina (SL) (316.34 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/sl/documents/product-information/arsenic-trioxide-medac-epar-product-information_sl.pdf)

Suomi (FI) (283.53 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/fi/documents/product-information/arsenic-trioxide-medac-epar-product-information_fi.pdf)

svenska (SV) (251.08 KB - PDF)

**First published:**

01/10/2020

**Last updated:**

26/04/2022

[View](/sv/documents/product-information/arsenic-trioxide-medac-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0003 22/04/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Arsenic trioxide medac : EPAR - All authorised presentations

English (EN) (15.55 KB - PDF)

**First published:** 01/10/2020

[View](/en/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-1)

български (BG) (35.31 KB - PDF)

**First published:**

01/10/2020

[View](/bg/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.73 KB - PDF)

**First published:**

01/10/2020

[View](/es/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_es.pdf)

čeština (CS) (30.87 KB - PDF)

**First published:**

01/10/2020

[View](/cs/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (13.64 KB - PDF)

**First published:**

01/10/2020

[View](/da/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.82 KB - PDF)

**First published:**

01/10/2020

[View](/de/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (13.74 KB - PDF)

**First published:**

01/10/2020

[View](/et/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (33.81 KB - PDF)

**First published:**

01/10/2020

[View](/el/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_el.pdf)

français (FR) (13.54 KB - PDF)

**First published:**

01/10/2020

[View](/fr/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (40.14 KB - PDF)

**First published:**

01/10/2020

[View](/hr/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (13.63 KB - PDF)

**First published:**

01/10/2020

[View](/is/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_is.pdf)

italiano (IT) (13.56 KB - PDF)

**First published:**

01/10/2020

[View](/it/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (33.3 KB - PDF)

**First published:**

01/10/2020

[View](/lv/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (31.22 KB - PDF)

**First published:**

01/10/2020

[View](/lt/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (21.77 KB - PDF)

**First published:**

01/10/2020

[View](/hu/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (30.78 KB - PDF)

**First published:**

01/10/2020

[View](/mt/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (13.15 KB - PDF)

**First published:**

01/10/2020

[View](/nl/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.65 KB - PDF)

**First published:**

01/10/2020

[View](/no/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_no.pdf)

polski (PL) (31.21 KB - PDF)

**First published:**

01/10/2020

[View](/pl/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.85 KB - PDF)

**First published:**

01/10/2020

[View](/pt/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_pt.pdf)

română (RO) (31.12 KB - PDF)

**First published:**

01/10/2020

[View](/ro/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (31.58 KB - PDF)

**First published:**

01/10/2020

[View](/sk/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (20.59 KB - PDF)

**First published:**

01/10/2020

[View](/sl/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (13.54 KB - PDF)

**First published:**

01/10/2020

[View](/fi/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.59 KB - PDF)

**First published:**

01/10/2020

[View](/sv/documents/all-authorised-presentations/arsenic-trioxide-medac-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Arsenic trioxide medac Active substance arsenic trioxide International non-proprietary name (INN) or common name arsenic trioxide Therapeutic area (MeSH) Leukemia, Promyelocytic, Acute Anatomical therapeutic chemical (ATC) code L01XX27

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:

- Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 10³/?l) in combination with all-trans-retinoic acid (ATRA)
- Relapsed/refractory APL (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR?) gene.

The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

## Authorisation details

EMA product number EMEA/H/C/005218

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

medac Gesellschaft für klinische Spezialpräparate mbH

Theaterstrasse 6

Opinion adopted 23/07/2020 Marketing authorisation issued 17/09/2020 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Arsenic trioxide medac : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (136.98 KB - PDF)

**First published:** 26/01/2022

**Last updated:** 26/04/2022

[View](/en/documents/procedural-steps-after/arsenic-trioxide-medac-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Arsenic trioxide medac : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/411838/2020

English (EN) (384.22 KB - PDF)

**First published:** 01/10/2020

[View](/en/documents/assessment-report/arsenic-trioxide-medac-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Arsenic trioxide medac

Adopted

Reference Number: EMA/CHMP/383424/2020

English (EN) (180.21 KB - PDF)

**First published:** 24/07/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-arsenic-trioxide-medac_en.pdf)

#### News on Arsenic trioxide medac

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020) 24/07/2020

#### Related content

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 26/04/2022

## Share this page

[Back to top](#main-content)